KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Shares Outstanding (Weighted Average) (2016 - 2025)

Nektar Therapeutics (NKTR) has 15 years of Shares Outstanding (Weighted Average) data on record, last reported at $18.9 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 39.12% year-over-year to $18.9 million; the TTM value through Sep 2025 reached $18.9 million, up 39.12%, while the annual FY2024 figure was $205.7 million, 8.24% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $18.9 million in Q3 2025 per NKTR's latest filing, up from $14.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $210.9 million in Q1 2025 and bottomed at $13.5 million in Q2 2024.
  • Average Shares Outstanding (Weighted Average) over 5 years is $153.0 million, with a median of $186.8 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Weighted Average): tumbled 92.89% in 2024, then surged 39.12% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $183.3 million in 2021, then rose by 2.09% to $187.1 million in 2022, then rose by 1.53% to $190.0 million in 2023, then rose by 8.24% to $205.7 million in 2024, then crashed by 90.79% to $18.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $18.9 million in Q3 2025, $14.1 million in Q2 2025, and $210.9 million in Q1 2025.